Clinical Study of the Safety and Efficacy of ASCT Combined With CD7-CART in the Treatment of CD7+ TCL

Trial Details

NCT ID

NCT07106723

Phase

PHASE2

Sponsor

Institute of Hematology & Blood Diseases Hospital, China

Status

RECRUITING

Cancer Type

Lymphoma

Interventions

• ASCT+CD7-CART

Locations (sample)

• Tianjin, Tianjin Municipality, China|39.14222,117.17667

Key Eligibility Criteria

• With the subject's consent and having signed the informed consent form, willing and capable of adhering to the planned visits, study treatment, lab…
• Age 18 to 65 years old, both male and female;
• Confirmed as T-cell non-Hodgkin's lymphoma type (including T-lymphoblastic lymphoma/leukemia) according to the World Health Organization's classifi…
• Confirmed as tumor cells expressing CD7 by histopathology and/or cytology at the time of screening;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.